723MO - Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
Vergote, et al.
Both 1L TV + carbo and 2L/3L TV + pembro had encouraging antitumor activity with acceptable safety profiles in pts with r/mCC.Table: 723MO
724MO - Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)
David O'Malley, et al.
The combination regimen of bal plus zal demonstrated impressive response rates (including complete remissions), DOR, and OS in patients with previously treated R/M CC. Clinical benefit was highest in patients with PD-L1+ tumors, with activity also seen in the PD-L1- setting. The treatment regimen was well tolerated.
725MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Susana Banerjee, et al.
An intermittent dosing schedule of the combination of VS-6766 and defactinib has shown encouraging clinical activity in patients with recurrent LGSOC. These data support an ongoing registration-directed study of VS-6766 ± defactinib in patients with recurrent LGSOC (ENGOT-ov60/NCRI/GOG-3052; NCT04625270).
726MO - Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
Nicoletta Colombo, et al.
LEN + pembro provided meaningful efficacy improvements in pts with previously treated advanced EC across all histologies (including difficult to treat histologies), and irrespective of prior (neo)adjuvant tx, and platinum-free interval (PFI) from most recent platinum tx. Pts with 1 prior line of platinum had greater benefit than those with ≥1 line, supporting early use of LEN + pembro.Table: 726MO
LBA34 - Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
Joyce Liu, et al.
In NRG-GY004 pts, HRR status was driven by BRCAmt, correlated with overall prognosis, and was predictive of olap response vs chemo.
795MO - Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
David O'Malley, et al.
Pembro demonstrated robust and durable ORR (48%; CR, 14%), encouraging survival outcomes and manageable toxicity in pts with heavily pretreated, advanced MSI-H/dMMR EC, and is a promising treatment option in this setting.